title: ICAM-1 in acute myocardial infarction: a potential therapeutic target.
abstract: Current treatments for AMI centre on prompt restoration of epicardial coronary blood flow. Despite improvements, AMI is still associated with significant morbidity and mortality. Novel approaches are therefore keenly sought. Intercellular adhesion molecule-1 (ICAM-1, CD54) is a member of the immunoglobulin superfamily. It is implicated in neutrophil and monocyte-endothelial cell adhesion, processes contributing to myocardial neutrophil infiltration and microvascular coronary slow flow, both viewed as important to the pathophysiologic responses in AMI. ICAM-1 would therefore appear an important potential therapeutic target in this context, and is the subject of this review.
authors.affiliation: Vascular Biology Laboratory, ANZAC Medical Research Institute, Concord Repatriation General Hospital, Sydney, Australia.
authors.forename: Victoria
authors.initials: V
authors.lastname: Benson
authors.forename: Aisling Clare
authors.initials: AC
authors.lastname: McMahon
authors.forename: Harry Claude
authors.initials: HC
authors.lastname: Lowe
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000502:physiology; D015870:Gene Expression; D006801:Humans; D066298:In Vitro Techniques; D018799:Intercellular Adhesion Molecule-1 / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D009203:Myocardial Infarction / Q000235:genetics / Q000503:physiopathology* / Q000628:therapy; D009504:Neutrophils / Q000502:physiology; D012995:Solubility
chemical_list: D000975:Antioxidants; D018799:Intercellular Adhesion Molecule-1